会议主要讨论的核心内容 - 公司有强劲的长期增长前景,在4个治疗领域包括创新管线和上市产品均有广度和深度 [7] - 公司在2024年上半年取得多项重要里程碑,包括获批新药和关键临床试验数据 [8][9][10] - 公司业务表现良好,第二季度收入同比增长20%,12个产品实现两位数增长 [9] - 公司在一般医疗、肿瘤、血液、免疫炎症和罕见病等领域均有重要产品和管线 [10][11][12] 问答环节重要的提问和回答 - 公司管线的现状和发展情况,管理层对管线的评估和信心 [15][16][17][18][19] - 公司MariTide的临床前景和预期,包括对其他代谢参数的影响 [25][26][27][28][29][30][31][32] - 公司Lp(a)降低药物olpasiran的临床设计和预期结果 [33][34][35][36][37][38][39] - 公司在心血管和代谢领域的产品协同和发展策略 [40][41][42] - 公司在肿瘤领域的新药xaluritamig的临床进展和预期 [43][44][45][46][47] - 公司UPLIZNA在重症肌无力适应症的临床试验进展和预期 [48][49][50][51][52][53] - 公司在MariTide等新药生产方面的规划和投资 [54][55][56][57][58][59]

A month has gone by since the last earnings report for Amgen (AMGN) . Shares have added about 5.8% in that time frame, underperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Amgen due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Q2 Earnings & Sales BeatAmgen’s second-quarter results were s ...

Amgen (AMGN) stock has risen 19.6% in the past six months compared with an increase of 12.4% for the industry. The stock has also outperformed the sector and the S&P 500 index, as seen in the chart below.AMGN Stock Outperforms Industry, Sector & S&P 500Image Source: Zacks Investment ResearchThe stock has also been consistently trading above its 50-day and 200-day moving averages since early August.One of the key reasons for the recent stock price outperformance has been its strong second-quarter results, as ...

会议主要讨论的核心内容 - 公司在四大领域(普通医疗、肿瘤、炎症和罕见疾病)的业务表现良好 [2][3][4] - 公司正在积极拓展国际市场 [3] - 公司对政策变化保持密切关注,认为《通胀减免法案》会对创新产生不利影响 [8][9][14][15] - 公司正在大力投资研发和生产能力建设,以应对新药上市后的供应挑战 [43][44][45][46][47][48] 问答环节重要的提问和回答 - 公司对即将到来的总统选举及其对行业的影响保持谨慎态度 [7][8] - 公司认为《通胀减免法案》会降低创新药物的回报,从而影响资本投入 [14][15] - 公司对新药MariTide的临床开发计划和商业化策略保持谨慎,不愿过多透露细节 [27][28][29][30][31][32] - 公司认为新药MariTide有望成为一款差异化的肥胖治疗药物,并有望在心血管、肾脏和肝脏疾病等领域发挥作用 [27][28][41][42] - 公司对新药rocatinlimab在皮肤病和呼吸系统疾病领域的临床前景保持谨慎乐观 [49][50] - 公司认为新药olpasiran针对高Lp(a)患者的临床价值很大,但需要解决检测和教育等市场准备工作 [51][52][53][54][55][56] - 公司正在大力投资人工智能技术,但目前还未产生重大突破性成果 [57][58][59][60]

THOUSAND OAKS, Calif., Aug. 30, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2024 Wells Fargo Healthcare Conference at 9:30 a.m. ET on Thursday, Sept. 5, 2024. Peter Griffith, executive vice president and chief financial officer at Amgen, and Jay Bradner, executive vice president of Research and Development and chief scientific officer at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, i ...

THOUSAND OAKS, Calif., Aug. 29, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Morgan Stanley 22nd Annual Global Healthcare Conference at 9:15 a.m. ET on Wednesday, Sept. 4, 2024. Robert A. Bradway, chairman and chief executive officer at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.The webcast, as with other selected presentations regarding developments ...

Amgen HQ in Thousand Oaks, CA JHVEPhoto Earlier this month, Wells Fargo cut its rating on Amgen (NASDAQ:AMGN), stating that success of its GLP-1 candidate MariTide was already priced into the shares. However, trading at 16.6x next year's earnings, the stock seems fairly valued despite 27% price appreciation over the past year. Existing product lines provide a strong foundation for the Amgen's valuation, while a successful conclusion to MariTide's crucial phase II study may provide a bullish catalyst later t ...

PeopleImages Since the publication of my last article, "Amgen: You Haven't Seen Anything Yet," Amgen's (NASDAQ:AMGN) share price has risen by more than 20%, thanks in part to increased speculative interest ahead of upcoming clinical results for MariTide in treating patients suffering from obesity, strong sales of its oncology and osteoporosis franchises, as well as medicines acquired in the Horizon Therapeutics deal. What will be presented in this article? I will discuss in detail several topics that ar ...

First and Only Pill for Children and Adolescents Ages 6-17 with Moderate to Severe Plaque PsoriasisTHOUSAND OAKS, Calif., Aug. 20, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced Otezla® (apremilast) is now available in the U.S. for pediatric use. Earlier this year, the U.S. Food and Drug Administration (FDA) approved Otezla for the treatment of moderate to severe plaque psoriasis in children and adolescents ages 6 and older who weigh at least 20 kg (44 lb) and are candidates for phototherapy or sy ...

Amgen has many growth opportunities ahead, and it also pays a fairly high dividend.If you're looking for a top healthcare company to invest in, you may want to consider looking at one that has multiple fast-growing products in its portfolio. By seeking out diversified growth stocks, you can minimize your risk and reduce significant volatility. If a company has a diverse product mix, it has many ways to grow its operations without being too dependent on a single asset.Amgen (AMGN -0.53%) is coming off a stro ...